Evidence map›Paper›PMID 32973273›Full record

ArticleScientific reports2020

Glucocorticoid-induced cell-derived matrix modulates transforming growth factor β2 signaling in human trabecular meshwork cells.

Felix Yemanyi, Janice Vranka, Vijay Krishna Raghunathan

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. To be or not to be - Decoding the Trabecular Meshwork Cell Identity.bioRxiv : the preprint server for biology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Felix YemanyiDepartment of Basic Sciences, College of Optometry, University of Houston, Houston, TX, USA.
Janice VrankaCasey Eye Institute, Oregon Health and Science University, Portland, OR, USA.
Vijay Krishna RaghunathanDepartment of Basic Sciences, College of Optometry, University of Houston, Houston, TX, USA. vraghunathan@uh.edu.
University of Houston · USOregon Health & Science University · US

Funding

Proteomics CoreP30EY010572 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI John Peter Campbell · 1995 to 2026
$19.4M
Research Programming ModuleP30EY007551 · NEI · UNIVERSITY OF HOUSTON · PI Nimesh Bhikhu Patel · 1988 to 2026
$16.4M
Mechanotransduction in Aqueous Outflow Regulation and Open Angle GlaucomaR01EY026048 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ACOTT, TED S, RAGHUNATHAN, VIJAYKRISHNA · 2018 to 2021
$1.5M
NEI NIH HHS EY026048-01A1NEI NIH HHS P30 EY007551NEI NIH HHS P30 EY010572NEI NIH HHS R01 EY026048
6 · The paper itself

Abstract

Aberrant remodeling of trabecular meshwork (TM) extracellular matrix (ECM) may induce ocular hypertensive phenotypes in human TM (hTM) cells to cause ocular hypertension, via a yet unknown mechanism. Here, we show that, in the absence of exogenous transforming growth factor-beta2 (TGFβ2), compared with control matrices (VehMs), glucocorticoid-induced cell-derived matrices (GIMs) trigger non-Smad TGFβ2 signaling in hTM cells, correlated with overexpression/activity of structural ECM genes (fibronectin, collagen IV, collagen VI, myocilin), matricellular genes (connective tissue growth factor [CTGF], secreted protein, acidic and rich in cysteine), crosslinking genes/enzymes (lysyl oxidase, lysyl oxidase-like 2-4, tissue transglutaminase-2), and ECM turnover genes/enzymes (matrix metalloproteinases-MMP2,14 and their inhibitors-TIMP2). However, in the presence of exogenous TGFβ2, VehMs and GIMs activate Smad and non-Smad TGFβ2 signaling in hTM cells, associated with overexpression of α-smooth muscle actin (α-SMA), and differential upregulation of aforementioned ECM genes/proteins with new ones emerging (collagen-I, thrombospondin-I, plasminogen activator inhibitor, MMP1, 9, ADAMTS4, TIMP1); with GIM-TGFβ2-induced changes being mostly more pronounced. This suggests dual glaucomatous insults potentiate profibrotic signaling/phenotypes. Lastly, we demonstrate type I TGFβ receptor kinase inhibition abrogates VehM-/GIM- and/or TGFβ2-induced upregulation of α-SMA and CTGF. Collectively, pathological TM microenvironments are sufficient to elicit adverse cellular responses that may be ameliorated by targeting TGFβ2 pathway.

Indexed as

Extracellular MatrixGlucocorticoidsHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9Protein Glutamine gamma Glutamyltransferase 2Protein-Lysine 6-OxidaseSignal TransductionTrabecular MeshworkTransforming Growth Factor beta2GlucocorticoidsLOX protein, humanMatrix Metalloproteinase 2Matrix Metalloproteinase 9Protein Glutamine gamma Glutamyltransferase 2Protein-Lysine 6-OxidaseTGM2 protein, humanTransforming Growth Factor beta2

Identifiers

PMID32973273
PMCPMC7518434
OpenAlexW3087906631

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.